Giuseppe Ermondi

University of Turin — Italy

Computer Science · Physical Sciences

35h-index3.7kcitations166works12.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Computational Drug Discovery Methods(56), Analytical Chemistry and Chromatography(34), Protein Degradation and Inhibitors(15), Metal complexes synthesis and properties(12), Chemical Synthesis and Analysis(12)

Publications166 total

Linker Methylation as a Strategy to Enhance PROTAC Oral Bioavailability: Insights from Molecular Properties and Conformational Analysis
Journal of Medicinal Chemistry·2025· 5 citedOpen Access
Macrocyclization: Enhancing Drug-like Properties of Discoidin Domain Receptor Kinase Inhibitors
ACS Medicinal Chemistry Letters·2025Open Access
Restoring adapter protein complex 4 function with small molecules: an in silico approach to <scp>spastic paraplegia 50</scp>
Protein Science·2024· 3 citedOpen Access
Molecular properties, including chameleonicity, as essential tools for designing the next generation of oral beyond rule of five drugs
ADMET & DMPK·2024· 9 citedOpen Access
Preclinical alternative drug discovery programs for monogenic rare diseases. Should small molecules or gene therapy be used? The case of hereditary spastic paraplegias
Drug Discovery Today·2024· 5 citedOpen Access
IMHB-Mediated Chameleonicity in Drug Design: A Focus on Structurally Related PROTACs
Journal of Medicinal Chemistry·2024· 22 cited
Exploring the chemical space of orally bioavailable PROTACs
Drug Discovery Today·2024· 45 citedOpen Access
DegraderTCM: A Computationally Sparing Approach for Predicting Ternary Degradation Complexes
ACS Medicinal Chemistry Letters·2023· 13 citedOpen Access
Chamelogk: A Chromatographic Chameleonicity Quantifier to Design Orally Bioavailable Beyond-Rule-of-5 Drugs
Journal of Medicinal Chemistry·2023· 36 citedOpen Access
High-throughput and reliable assessments of the ionization constant of monoprotic organic acids through an arginine based mixed mode HPLC
Journal of Pharmaceutical and Biomedical Analysis·2023· 1 citedOpen Access
The Quest for Oral PROTAC drugs: Evaluating the Weaknesses of the Screening Pipeline
ACS Medicinal Chemistry Letters·2023· 22 citedOpen Access
Ionization and lipophilicity in nonpolar media mimicking the cell membrane interior
Bioorganic & Medicinal Chemistry·2023· 16 cited
In Silico Tools to Extract the Drug Design Information Content of Degradation Data: The Case of PROTACs Targeting the Androgen Receptor
Molecules·2023· 7 citedOpen Access
Conformational Sampling Deciphers the Chameleonic Properties of a VHL-Based Degrader
Pharmaceutics·2023· 21 citedOpen Access
Deleterious, protein-altering variants in the transcriptional coregulator ZMYM3 in 27 individuals with a neurodevelopmental delay phenotype
The American Journal of Human Genetics·2022· 15 citedOpen Access
Personalized Treatment for Infantile Ascending Hereditary Spastic Paralysis Based on In Silico Strategies
Molecules·2022· 5 citedOpen Access
Deleterious, protein-altering variants in the X-linked transcriptional coregulator <i>ZMYM3</i> in 22 individuals with a neurodevelopmental delay phenotype
2022Open Access
Refinement of Computational Access to Molecular Physicochemical Properties: From Ro5 to bRo5
Journal of Medicinal Chemistry·2022· 27 citedOpen Access
Designing Soluble PROTACs: Strategies and Preliminary Guidelines
Journal of Medicinal Chemistry·2022· 81 citedOpen Access
Ionization and Lipophilicity in Nonpolar Media Mimicking the Cell Membrane Interior
SSRN Electronic Journal·2022Open Access
page 1 of 9Next →

Frequent Co-authors

Giulia Caron(39), Maura Vallaro(12), Matteo Rossi Sebastiano(7), Diego García Jiménez(7), Jan Kihlberg(6), Roberta Fruttero(6), Silvio Aime(5), Mauro Botta(5), Vasanthanathan Poongavanam(5), Alberto Gasco(5), Gilles H. Goetz(5), Bernard Testa(5), Marina Shalaeva(4), Pierre‐Alain Carrupt(4), Fulvio Uggeri(3), Antonella Di Stilo(3), Máté Erdélyi(3), Mauro Ravera(3), Elisabetta Gabano(3), Domenico Osella(3)